Crescent Biopharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants

Crescent Biopharma (Nasdaq: CBIO), a clinical-stage oncology biotechnology company, announced the pricing of an underwritten public offering of 8.1 million ordinary shares at $14.50 per share and 525,897 pre-funded warrants at $14.499 per warrant, expected to raise approximately $125 million in gross proceeds. The offering is expected to close on July 16, 2026, with underwriters granted a 30-day option to purchase an additional 1.3 million shares.